Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 27Lenalidomide 22Cyclophosphamide 20Prednisone 14Vincristine 12obinutuzumab 11Magnetic Resonance Spectroscopy 11Doxorubicin 11Specimen Handling 9Bendamustine Hydrochloride 8ibrutinib 7Biopsy 7pembrolizumab 6fludarabine 6fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Etoposide 4CT-P10 4Prednisolone 3Mycophenolic Acid 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Follicular × loncastuximab tesirine × 90 days × Clear all
NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04998669 2026-03-23

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

University of Miami

Phase 2 Recruiting
100 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡